Related by context. All words. (Click for frequent words.) 82 Fast Track Status 81 Fast Track Designation 78 Orphan Status 78 Orphan Drug status 77 Orphan Drug designation 75 Orphan Designation 73 Orphan Drug Designation 73 orphan designation 71 Marketing Authorisation Application 71 Receives Orphan Drug Designation 71 Orphan Medicinal Product 71 Granted Orphan Drug 70 Phase III Clinical Trial 70 Orphan Drug designations 69 Meets Primary Endpoint 69 Positive Opinion 69 Marketing Authorization Application 69 Orphan designation 69 Marketing Authorisation 69 Civacir 69 Files IND 69 Marketing Authorization 69 FDA Orphan Drug 69 OMP designation 69 Pivotal Phase III 68 Phase III Trial 68 Phase IIb Trial 68 Dupuytren Contracture 68 Drug Candidate 68 Phase 2b Clinical Trial 68 Receives Positive Opinion 68 Expanded Indication 68 Patent Covering 67 orphan medicinal product 67 FDA Accepts 67 Initiate Clinical Trial 67 Fast Track designation 67 Fast Track designations 67 Receives Marketing Authorization 67 Psoriasis Drug 67 Phase III Trials 67 Cellegesic 67 Vandetanib 67 Patient Enrollment 67 Trobalt 67 Accelerated Approval 67 Priority Review 66 Pivotal Trial 66 Icatibant 66 FDA Clearance 66 TEMODAL 66 Completes Patient Enrollment 66 Preotact R 66 Investigational Treatment 66 Receives Orphan Drug 66 SNT MC# 66 Advagraf 66 Patients Treated With 66 GTC recombinant human 66 Adjuvant Treatment 66 NDA Submission 66 Phase 2a Trial 66 Orphan Drug 66 Pafuramidine 66 Pivotal Study 66 Bendamustine 66 Soliris TM eculizumab 65 FDA Approvals 65 IND Application 65 Generic Version 65 Granulocyte Colony Stimulating Factor 65 Zebinix R 65 Milestone Payment 65 Ciclesonide 65 Bayer Onyx 65 Torisel 65 Supplemental Biologics License Application 65 Genasense R 65 Noxafil 65 Mylan Receives Approval 65 Marketing Authorization Applications 65 Zenpep 65 Cutaneous T 65 Metastatic Colorectal Cancer 65 Initiates Enrollment 65 Product Designation 65 Lambert Eaton Myasthenic 65 Investigational Compound 65 Submits NDA 65 Raptiva ® 65 refractory chronic lymphocytic 65 Sanvar R 65 Patient Enrolment 65 FOLOTYN ® 65 Milestone Payments 65 Mutual Recognition Procedure 64 Febuxostat 64 ATryn ® 64 Combination REOLYSIN R 64 Alvesco R 64 SYCREST 64 PDUFA Date 64 #D#C# 64 Kit CD# positive 64 Phase IIb Clinical Trial 64 BRILINTA 64 Romiplostim 64 Demonstrates Significant 64 Evoltra ® 64 Prostate Cancer Vaccine 64 Pazopanib 64 Achieves Primary Endpoint 64 Aviptadil 64 Marketing Authorization Application MAA 64 receptor tyrosine kinase inhibitor 64 Trovax 64 Bayer Nexavar 64 Amrubicin 64 Loramyc R 64 Irinotecan 64 Dacogen injection 64 Syndrome LEMS 64 OMAPRO ™ 64 TORISEL TM 64 Pixantrone 64 R lenalidomide 64 CE Marked 64 Recombinant Human 64 Iluvien ® 64 Mimpara 64 Peginterferon alfa 2b 64 Lenalidomide 64 Mepact 64 PrevOnco 64 Evoltra 64 rasagiline tablets 64 FDA Approvable Letter 64 Aryplase 64 Systemic Delivery 64 Safinamide 64 Tostrex 64 Investigational Device Exemption 64 UPLYSO 64 Clofarabine 64 Severe Sepsis 64 Personalized Immunotherapy 64 Dyloject TM 64 Pirfenidone 63 rilonacept 63 Kepivance 63 Acute Attacks 63 Initiates Phase III 63 Ranolazine 63 DOXIL R 63 Successfully Completes Phase 63 Phase 2a Clinical Trial 63 Pivotal Clinical Trial 63 Raptiva R 63 Yondelis ® 63 Trial Evaluating 63 Nimotuzumab 63 Improved Survival 63 REBETOL combination therapy 63 acetonide FA 63 SEBIVO 63 Announces Tentative Approval 63 TRISENOX ® 63 Vitrasert R 63 Alvesco ® 63 Receives Fast Track 63 Clevudine 63 Nexavar ® 63 Firazyr 63 Advanced Melanoma 63 STELARA TM 63 Esbriet pirfenidone 63 Catena ® 63 Arimoclomol 63 Somatuline Autogel 63 Files Investigational 63 miconazole Lauriad R 63 Interferon Alpha 63 Initiates Clinical Trial 63 Increlex R 63 sorafenib tablets 63 TO AVOID PREGNANCY WHILE 63 Initiates Phase II 63 Preotact 63 Sapacitabine 63 TORISEL 63 Application MAA 63 Initiates Clinical 63 Pegloticase 63 Maribavir 63 IND Filing 63 Receives Approvable Letter 63 IL# PE#QQR 63 RELISTOR ® 63 PROMACTA 63 Gleevec Glivec 63 Pivotal Phase 63 liver resection surgeries 63 TRANSDUR ™ 63 Begin Clinical Trials 63 ANDA Filing 63 Interferon Beta 63 SFDA Approval 63 Evoltra TM 63 Opterone R 63 Everolimus 63 Loramyc 63 Azacitidine 63 Centralized Procedure 63 Torisel temsirolimus 63 Vidaza R 63 Alemtuzumab 63 Retacrit 63 Nabi HB Intravenous 63 MabCampath 63 novel emulsion formulation 63 Japanese Encephalitis Vaccine 63 oropharyngeal candidiasis 63 FDA Approval 63 Methylnaltrexone 63 Roche Actemra 63 Junovan 63 PGL# 62 Microplasmin 62 Initiates Clinical Trials 62 Epratuzumab 62 Fabry Disease 62 Taro Receives 62 Ridaforolimus 62 Marketing Authorisation Application MAA 62 Initiate Phase 62 Prodarsan 62 Pivotal Trials 62 Mycophenolate Mofetil 62 Cethromycin 62 FIRAZYR 62 Tarceva TM 62 drug ISA# 62 Tacrolimus 62 acyclovir Lauriad R 62 Glatiramer Acetate 62 Adjunctive Therapy 62 Disease Modifying 62 VIVITROL ® 62 Genasense ® 62 Tigecycline 62 Prolongs Survival 62 beta 1a 62 REVLIMID R 62 Fingolimod 62 GTC recombinant form 62 Somatuline R Autogel R 62 BENLYSTA ® 62 Oral Cladribine 62 SinuNase TM 62 JAK Inhibitor 62 Drug Eluting Stent System 62 histamine dihydrochloride 62 Phase 1b Clinical Trial 62 LUCASSIN 62 rolling Biologics License 62 Tezampanel 62 Confirmatory Phase 62 Romidepsin 62 generation purine nucleoside 62 Myelodysplastic Syndromes 62 Nexavar sorafenib 62 Fibrillex TM 62 Milestone Payment From 62 Certican 62 Receives Milestone Payment 62 Archexin 62 TYKERB 62 Bosutinib 62 Improves Survival 62 Etravirine 62 SPRYCEL ® 62 Fludara ® 62 Campath ® 62 Cx# [002] 62 Protease Inhibitor 62 Lung Cancer Drug 62 StaphVAX R 62 vinorelbine emulsion 62 Ecallantide 62 Rheumatoid Arthritis Drug 62 FDA APPROVES 62 Tasigna nilotinib 62 TheraCIM 62 Cloretazine ® 62 Brentuximab Vedotin SGN 62 YONDELIS 62 Friedreich Ataxia FRDA 62 Neo Bladder Augment 62 Dose Ranging Study 62 Presents Positive 62 Soft Tissue Sarcoma 62 ORENCIA R 62 Immunosuppressant 62 Esbriet ® 62 ELAPRASE 62 Lubiprostone 62 Hsp# Inhibitor 62 Regulatory Approval 62 Patent Broadly Covering 62 Filgrastim 62 MEZAVANT 62 Hepatitis B Vaccine 62 Metastatic Melanoma 62 Loramyc ® 62 methylnaltrexone 62 ATryn R 62 R bendamustine hydrochloride 62 CONBRIZA 62 Cimzia certolizumab pegol 62 Receives CE Marking 62 RAPTIVA 62 Monoclonal Antibody 62 Schizophrenia Drug 62 GRAS Status 62 Golimumab 62 Kuvan R 62 Clolar ® 62 Ixempra 62 Angiox ® 62 oropharyngeal candidiasis OPC 62 Alitretinoin 62 Onconase 62 Degarelix 62 Completes Enrollment 62 IRESSA 62 Premarket Approval 62 Ceflatonin R 62 induced macular edema 62 Brilique 62 Clinical Trial Results 62 Grants Orphan Drug 62 RhuDex ® 62 Campath alemtuzumab 62 EVIZON TM 62 dasatinib Sprycel ® 62 Ganciclovir 62 Complicated Skin 62 Octreolin 62 Pneumococcal Vaccine 62 highly purified pasteurized 62 Therapeutic Vaccine 62 DC Bead 62 Malignant Melanoma 62 Neupro R 62 Combination Therapy 62 GW# [003] 62 vapreotide acetate 62 MAA submission 62 pediatric Crohn disease 62 registrational studies 62 intranasal formulation 62 AZILECT R 61 MyVax R 61 XIAPEX ® 61 Liprotamase 61 Revolade 61 omacetaxine mepesuccinate 61 Levoleucovorin 61 k Clearance 61 Regenerative Cells 61 Ambrisentan 61 Gout Drug 61 Phase IIIb clinical 61 Pemetrexed 61 NOVARTIS 61 Million Milestone Payment 61 ORENCIA ® 61 SUPPRELIN R LA 61 Advanced Renal Cell 61 MAGE A3 ASCI 61 Bafetinib 61 Sagent Pharmaceuticals Announces 61 sapropterin dihydrochloride 61 DepoDur 61 HDAC Inhibitor 61 Betaseron ® 61 Complete Response 61 NOXAFIL 61 SANVAR 61 Pfizer Sutent 61 LUVENIQ 61 Biologic License Application BLA 61 Wafer polifeprosan 61 Wyeth Torisel 61 Pradefovir 61 Zorbtive TM 61 systemic immunosuppressive drugs 61 Immunotherapeutic 61 Albuferon TM 61 Xanafide 61 VISICOL R 61 ISTODAX ® 61 Ofatumumab 61 PEGylated anti 61 Antitumor Activity 61 Cimzia ® certolizumab pegol 61 Glufosfamide 61 Carbidopa 61 #k Clearance 61 Cancidas 61 sitaxsentan sodium 61 Oracea ® 61 FDA Clears 61 Insegia 61 StemEx 61 Phase IIa Clinical Trial 61 Darunavir 61 KIACTA ™ 61 Dapagliflozin 61 ACOMPLIA R 61 TYZEKA 61 orally administered inhibitor 61 Acute Ischemic Stroke 61 Investigational Agent 61 JAK2 Inhibitor 61 Oral Spray 61 cinacalcet HCl 61 Troxatyl 61 Sunesis Pharma 61 chronic idiopathic thrombocytopenic purpura 61 Submits Response 61 alfa 2a 61 #mg Tablets [002] 61 Transdermal Patch 61 Temsirolimus 61 alvimopan 61 ONGLYZA ™ 61 Nitazoxanide 61 Phase 2b Study 61 Is Well Tolerated 61 Plenaxis R 61 Calcitonin 61 sunitinib Sutent 61 ONGLYZA TM 61 vemurafenib 61 Mimpara R 61 PRN FDA Approves 61 myelodysplastic myeloproliferative diseases 61 Novel Oral 61 Loxapine 61 ThermoDox R 61 Ticagrelor 61 HepaGam B 61 Neulasta ® 61 Daclizumab 61 Diabetic Macular Edema 61 II Clinical Trial 61 Velaglucerase Alfa 61 Temodar ® 61 Enzyme Replacement Therapy 61 Hormone Refractory Prostate Cancer 61 RoACTEMRA 61 Rhucin ® recombinant 61 successfully commercialize Iluvien 61 Phase 2b Trial 61 oral prodrug 61 Biologics License Application 61 Tracleer r 61 Pregabalin 61 Li Fraumeni Syndrome 61 Exclusive License 61 Conditional Approval 61 Gaucher Disease 61 Luveniq 61 targeted radiotherapeutic 61 eltrombopag 61 Serostim ® 61 Tamibarotene 61 HP Acthar Gel repository 61 novel VDA molecule 61 Panzem R 61 Phase III Clinical Trials 61 ixabepilone 61 Argatroban 61 REVLIMID ® 61 PNP inhibitor 61 Clinical Trial Evaluating 61 Bevacizumab 61 PDE4 inhibitor 61 Zebinix 61 C1 Inhibitor 61 Xyfid TM 61 Expedited Review 61 ATL# [001] 61 Prodarsan R 61 ONCASPAR 61 Actemra tocilizumab 61 Octreotide 61 lucinactant 61 Soliris eculizumab 61 Aflibercept 61 docetaxel Taxotere ® 61 Allovectin 7 R 61 Onco TCS 61 Prestara 61 Ceflatonin 61 Present Preclinical Data 61 polymerase inhibitor 61 Telzir 61 HepeX B 61 relapsing remitting MS RRMS 61 Gleevec imatinib mesylate 61 Eculizumab 61 Entereg TM 60 Immune Globulin Human 60 Edurant 60 Study Evaluating 60 Iluvien TM 60 mertansine 60 Efficacy Trial 60 PEGylated Fab fragment 60 Pralatrexate 60 GATTEX TM 60 SYN# 60 PREOS R 60 Cerepro 60 Biological License Application 60 ATG Fresenius S 60 Silodosin 60 Oral Mucositis 60 ARIXTRA R 60 Decentralized Procedure 60 Phase #b/#a clinical 60 Orazol 60 severe hypercholesterolemia 60 Iloperidone 60 Annamycin 60 Treated Patients 60 Factor VIIa 60 YONDELIS R 60 silodosin 60 Eltrombopag 60 Troxatyl TM 60 Dasatinib 60 refractory acute promyelocytic 60 Vaccine Candidate 60 reslizumab 60 Spiegelmer ® 60 lexidronam injection 60 Dalbavancin 60 Ranibizumab 60 Tetrabenazine 60 Jevtana 60 Stem Cell Treatment 60 Monotherapy 60 Release Capsules 60 Long Term Efficacy 60 palifermin 60 Cimzia TM 60 Vion Pharmaceuticals 60 Cethrin R 60 phase IIb clinical 60 etanercept Enbrel 60 Allovectin 7 60 AMEVIVE 60 1mg tablets 60 Zenvia Phase III 60 Diabetic Ulcers 60 Presents Preclinical Data 60 Shows Efficacy 60 Lupus Drug 60 Epilepsy Drug 60 topically administered 60 Hexvix ® 60 albinterferon alfa 2b 60 Cholesterol Lowering Drug 60 Somatuline Depot 60 subependymal giant cell 60 MOVIPREP R 60 G#DT 60 hoFH 60 Systemic Sclerosis 60 SomatoKine 60 CINTREDEKIN BESUDOTOX 60 ALN PCS 60 Well Tolerated 60 ATryn ® GTC recombinant 60 Medicinal Products EMEA 60 Allovectin 7 r 60 RESOLOR 60 TroVax ® 60 Generic Versions 60 severe gastroparesis 60 MEK Inhibitor 60 Azathioprine 60 Palifosfamide 60 Begins Dosing 60 Sevelamer 60 THELIN 60 TNF Tumor Necrosis Factor 60 opioid induced constipation OIC 60 Besivance 60 ALN HPN 60 Thalidomide Pharmion 60 human C1 inhibitor 60 FOR FURTHER INFORMATION ABOUT 60 Efficacy Results 60 Navelbine ® 60 Optimer Pharma 60 POSIDUR ™ 60 Receptor Agonist 60 REVLIMID lenalidomide 60 Sutent sunitinib 60 DIFICID ™ 60 miconazole Lauriad 60 Remicade infliximab 60 pancreatic insufficiency 60 Previously Treated 60 KRN# 60 RSR# 60 RECOTHROM R 60 Tasimelteon 60 cutaneous T 60 methylnaltrexone bromide 60 Abstral ® 60 Stedesa 60 Eraxis 60 Gamunex C 60 Zavesca r 60 Survival Benefit 60 ALVESCO R 60 BLA filing 60 Crofelemer budesonide foam 60 IV Busulfex 60 LymphoStat B belimumab 60 Tocilizumab 60 Submits Supplemental 60 Glybera R 60 treat chronic sinusitis 60 Intravenous Formulation 60 Actimmune ® 60 Interferon beta 1a 60 sublingual tablets 60 USFDA approval 60 Neoadjuvant 60 Afinitor ® 60 Pulmonary Arterial Hypertension 60 Demonstrates Potent 60 Thalomid ® 60 InNexus Biotechnology 60 IMiDs 60 Proquin XR 60 Rotavirus Vaccine 60 Reports Preclinical Data 60 Diabetic Neuropathy 60 Orally administered 60 HoFH 60 BioSTAR R 60 Oral Calcitonin 60 Intravenous Human 60 Tyrosine Kinase Inhibitor 60 Bezielle 60 Avastin bevacizumab 60 lymphoid malignancies 60 RhuDex 60 Deferiprone 60 ADVEXIN p# therapy 60 registrational trial 60 Testosterone Gel 60 histone deacetylase HDAC inhibitor 60 ruxolitinib 60 HCV Protease Inhibitor 60 Uvidem 60 Adenuric R 60 omega interferon 60 Single Dose 60 Generic Version Of 60 orphan drug 60 PrevOnco ™ 60 Cinacalcet HCl 60 European Medicines Evaluation 60 Dabigatran etexilate 60 Rhucin R 60 Calcium Acetate 60 HepaSphere 60 Vimpat R 60 thalidomide Thalomid 60 BiovaxID TM 60 Squamous 60 phase IIb trial 60 novel oral anticoagulant 60 Cancer Vaccine 60 Topotecan 60 Demonstrates Efficacy 60 Velcade bortezomib 60 Patients Treated 60 Toremifene 60 aripiprazole Abilify 60 rotigotine transdermal patch 60 ELIQUIS 60 VALSTAR 60 Sebivo 60 Loramyc ™ 60 Keppra ® levetiracetam 60 Preclinical Data 60 Congenital Emphysema 60 MOZOBIL 60 Elagolix 60 R sorafenib tablets 60 Augment ™ 60 Campto 60 Improves Outcomes 60 interferon gamma 1b 60 LHRH antagonist 60 Anticancer Compound 60 Voraxaze 60 Disease Progression 60 Onsolis 60 Orathecin 60 Inhalation Aerosol 60 Sycrest 60 Pharmacokinetics PK 60 Cloretazine 60 Belinostat 60 IIa Clinical Trial 60 Firazyr ® 60 Orapred ODT 60 TELINTRA 60 Parathyroid Hormone 60 Treatment Regimen 60 Mouse Model 60 Mipomersen 60 SABER ™ 60 Etanercept 60 Laquinimod 60 Prestara TM 60 Replacement Therapy 60 Perifosine 60 dirucotide MBP# 60 Initiate Phase II 60 Melphalan 60 Levofloxacin 60 Vidaza azacitidine 60 CryoSeal FS System 60 DORIBAX 60 AZILECT ® 59 Anastrozole 59 Bucindolol 59 Clinical Trial Application 59 Boceprevir 59 investigational humanized monoclonal antibody 59 phase III isavuconazole 59 Medoxomil 59 First Patient Treated 59 Angiox 59 k Premarket Notification 59 First Patient Dosed 59 Onalta 59 Gene Therapy Trial 59 Treatment Experienced 59 CYT# potent vascular disrupting 59 Severe VOD 59 Onalta ™ 59 BrachySil TM 59 Rectogesic 59 Tesamorelin 59 HuMax TAC 59 Combination Treatment 59 hypereosinophilic syndrome 59 Panzem R NCD 59 Fludarabine 59 Inhaled Insulin 59 Oral Fingolimod 59 Myelodysplastic Syndrome MDS 59 Augment TM 59 GA GCB 59 Modrenal R 59 tezampanel NGX# 59 CHMP recommendation 59 Aloxi R 59 Vicriviroc 59 CLIA waiver 59 Zenapax 59 granted orphan medicinal 59 Nabi HB R 59 Delayed Release 59 PANVAC VF 59 Biologic License Application 59 Satraplatin 59 OMNARIS HFA 59 prokinetic agent 59 Increlex ® 59 Emselex 59 Anthim 59 Ozarelix 59 Bazedoxifene 59 metastatic malignant 59 Gets FDA Clearance 59 Tibotec Therapeutics division 59 LEUKINE 59 oral methylnaltrexone 59 CTAP# Capsules 59 ORADUR ® 59 HuMax CD4 59 Phase IIIb study 59 Anti Tumor Activity 59 BioSante Pharmaceuticals Announces 59 huN# DM1 59 Chronic Hepatitis B 59 liposomal formulation 59 PROSTASCINT R 59 Clinical Trial Data 59 CIP TRAMADOL ER 59 Oncoscience AG 59 IV acetaminophen 59 Entecavir 59 Naglazyme 59 lintuzumab SGN 59 oral ridaforolimus 59 Diamyd ® 59 Taxotere docetaxel 59 ELADUR ™ 59 Regulatory Clearance 59 Omacetaxine 59 alefacept 59 COLAZAL R 59 Arzerra ofatumumab 59 nanofiltered plasma derived 59 Oxaliplatin 59 Signaling Pathway 59 BARACLUDE R 59 Maraviroc 59 Rilonacept 59 Seasonal Influenza Vaccine 59 Entocort 59 Myeloid 59 TRISENOX 59 TYGACIL 59 Taxotere ® 59 thetreatment 59 Infected Patients 59 Submits Biologics License Application 59 2 inhibitor CYT# 59 Hematological Malignancies 59 Approvable 59 Lenocta TM 59 Rhucin ® 59 Keryx Biopharma 59 IMA# 59 GlycoPEG GCSF 59 Sensipar R 59 tuberous sclerosis TS 59 AstraZeneca Iressa 59 histone deacetylase inhibitor 59 Blood Pressure Drug 59 Topical Gel 59 MEPACT 59 Combidex 59 ROTATEQ 59 FRDA 59 EFAPROXYN 59 Rasagiline 59 Vasovist 59 amifampridine phosphate 59 Commence Phase 59 Cerepro ® 59 sunitinib malate 59 MGd 59 Receives Complete Response 59 Newly Diagnosed Multiple Myeloma 59 Firdapse 59 BYETTA ® 59 Shows Statistically Significant 59 supplemental Biologics License Application 59 THALOMID R 59 Shows Promise Against 59 Colorectal Cancer Patients 59 Metformin GR 59 Serdolect ® 59 HepaGam B TM 59 diarrhea predominant irritable 59 R adalimumab 59 Fluconazole 59 Progenitor Cells 59 Ganite ® 59 Tracleer R 59 Rifaximin 59 Doripenem 59 Osteoporosis Drug 59 Ocrelizumab 59 Relapsed Refractory 59 Lung Cancer Trial 59 Multiferon 59 Omapro 59 Japanese Encephalitis vaccine 59 Aliskiren 59 Metformin HCl 59 Denufosol 59 adalimumab Humira 59 relapsing multiple sclerosis 59 Erlotinib 59 MPS VI 59 Teva Provides Update 59 Arranon 59 Fondaparinux 59 REPLAGAL 59 Tolvaptan 59 Initiates Phase 59 ZEGERID Chewable Tablets 59 ZACTIMA 59 Adjuvant Therapy 59 IV APAP 59 Mitoxantrone 59 Improve Survival 59 Advexin 59 Aplidin 59 Santhera 59 Extended Release Capsules 59 Lipsovir ® 59 COPEGUS R 59 Phase IIb trials 59 ADP receptor antagonist 59 Voreloxin 59 delivers fluocinolone acetonide FA 59 Aurexis 59 granted orphan 59 pioglitazone HCl 59 Fodosine 59 Phase IIB 59 Application BLA 59 PHASE III 59 Regeneron Pharma 59 Dose Escalation 59 ISTODAX 59 RNAi Therapeutics 59 ADVEXIN 59 XIAPEX 59 AVASTIN 59 Thrombin 59 Vascular Wrap TM 59 Investigational Drug 59 terlipressin 59 rheumatoid arthritis psoriatic arthritis 59 arthritis PsA 59 Azedra 59 Forodesine HCl 59 OncoGel 59 CIMZIA r 59 Qualified Therapeutic Discovery 59 Roflumilast 59 IgG1 monoclonal antibody 59 Teysuno 59 Hepatocellular Carcinoma 59 GABITRIL 59 Vicinium TM 59 PRIALT 59 Uracyst 59 systemic fungal infections 59 Drug Submission 59 ZALBIN 59 Cinryze ™ 59 SCHWARZ PHARMA 59 Teriparatide 59 BLA submission 59 Randomized Phase 59 PresbyLens ® 59 CAELYX 59 Nexavar sorafenib tablets 59 CE Marking 59 rufinamide 59 Demonstrates Positive 59 Plicera 59 Epidermal Growth Factor Receptor 59 FUSILEV ® 59 Vpriv 59 ocular formulation 59 Telbivudine 59 Veregen TM 59 Chronic Hepatitis C 59 Vaccine Adjuvant 59 Arthritis Drug 59 miconazole MBT 59 Neulasta R 59 PEG IFN 59 Azixa 59 Vantas 59 SUTENT ® 59 OvaRex R 59 VitiGam TM 59 SUTENT 59 pan HDAC inhibitor 59 Regulatory Approvals 59 Submits IND 59 Allegra Oral Suspension 59 ZADAXIN ® 59 Interferon Alfa 59 Atypical Hemolytic Uremic Syndrome 59 Bioral Amphotericin B 59 ZEFTERA TM Zevtera TM